Tetrahydro-4H-pyran-4-one → 2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-9-(1-methyl-5-(1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)-1H-pyrazol-4-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine

Participants

Reaction Conditions

Reaction Steps

To a solution of 4-[3-methyl-1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-12-[1-methyl-5-(piperidin-3-yl)-1H-pyrazol-4-yl]-9-oxa-3,6-diazatricyclo[8.4.0.02,6]tetradeca1(14), 2,4,10,12-pentaene (60 mg, 0.13 mmol) and tetrahydropyran-4-one (26 mg, 0.26 mmol) in ethanol (10 mL) was added Ti(Oi-Pr)4 (74 mg, 0.26 mmol). After being stirred at 20° C. for 20 min, NaBH3CN (16 mg, 0.26 mmol) was added and stirred at 20° C. for 16 h. The solvent was removed and several drops of water were added. The solid was filtered off and the filtrate was evaporated to afford the crude product, which was purified by reverse phase Combiflash eluting with a 0-50% gradient of CH3CN in 0.3% NH4HCO3 to give 226 (35 mg, 50% yield). LCMS (ESI): RT=4.97 min, m/z: 557.4 [M+H+]. 1H NMR (500 MHz, MeOH-d4) δ 8.48 (d, J=8 Hz, 1H), 7.25 (s, 1H), 7.41 (s, 1H), 7.09 (d, J=8 Hz, 1H), 7.00 (s, 1H), 5.94 (t, J=13 Hz, 1H), 4.54 (d, J=5 Hz, 4H), 3.95 (d, J=6.5 Hz, 5H), 3.35 (t, J=25 Hz, 3H), 3.25 (s, 1H), 3.00 (d, J=6.5 Hz, 2H), 2.51-2.54 (m, 2H), 2.38 (s, 3H), 2.12 (d, J=11 Hz, 1H), 1.86-1.62 (m, 6H), 1.56-1.49 (m, 6H)

Provenance & Evidence